# OV01 Preference Label 1 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_297_Vasquell - Task 1, batch 20260615_082222).
Current status: DRAFT for read-and-own. No platform entry without Alexander's authorization for that exact step.

Studio-selected pair:
- Transcript A = 0.900, 15 steps, 11m 34s.
- Transcript B = 0.720, 15 steps, 5m 39s.
- Bundle IDs not shown in the pasted transcript; record from the download icons on submit.

Basis: both deliverable summaries read against `golden-OV01-v1.docx` and `grader-guidelines-OV01.txt`. The central capped failure for OV01 is continuing the carried-forward inpatient enoxaparin VTE prophylaxis at discharge (or carrying admission antibiotic dosing forward, or silently resuming or discontinuing a held agent). A 0.90 sits just under the 0.93 catcher; B 0.72 is a low pass above the 0.40 and 0.50 enoxaparin floors. The verdict is decided against that central failure, with the conservative-margin calibration the skill requires.

KEY FINDING: A is better. Both transcripts produce thorough line-by-line reconciliations and both correctly hold metformin, empagliflozin, and lisinopril with reasons, flag the non-culture-directed antibiotic for de-escalation, and exclude TMP-SMX for the sulfa allergy. Neither, however, executes the central golden move of discontinuing the carried-forward inpatient-only enoxaparin at discharge; both defer it to physician confirmation, so this pair is closer to partial-versus-partial on the central item than catch-versus-miss. A is meaningfully better because it does not mislabel enoxaparin's provenance and is more complete, whereas B explicitly calls enoxaparin "New (not on MAR/home list)," a provenance error on the exact item the task targets. The margin is A+ rather than A++ because A still does not affirmatively discontinue the inpatient-only prophylaxis.

VERDICT: A2 (A better). Button = A+ (one plus sign).

## Justification

Preferred output: A

Justification: The task's central failure is continuing the carried-forward inpatient enoxaparin VTE prophylaxis at discharge, or carrying admission antibiotic dosing forward, or silently resuming or discontinuing a held agent. Neither transcript signs enoxaparin as-is, and neither silently resumes a held agent, so both avoid the worst form of the central failure. A handles the surrounding reconciliation more faithfully and does not misstate enoxaparin's origin; B mislabels enoxaparin as new rather than carried-forward, which is a factual error on the central item. A is therefore better, but not much better, because A's enoxaparin verdict is change or conditional rather than the golden's discontinue-as-inpatient-only.

Prompt adherence: Both go line by line over all fourteen orders, write plain-language patient instructions, and flag confirm-before-sign items. Both answer the requested workflow. Tie on basic prompt adherence.

Correctness: A is better. Both correctly hold metformin and empagliflozin, defer lisinopril, retain acetaminophen with no NSAID, continue home insulin, and treat the antibiotic as non-culture-directed requiring de-escalation with TMP-SMX excluded. The deciding difference is enoxaparin provenance: B asserts it is "New (not on MAR/home list)"; A treats it as a carried-forward order. Neither discontinues it as an inpatient-only agent, which is the only reason this is not a clean catch.

Completeness: A is more complete: it surfaces the triple-antithrombotic bleeding risk explicitly, calls out the two dropped home meds (ferrous sulfate and cholecalciferol), and details the insulin specifics needed before sign. B also catches the two omitted home meds and is well organized, but is briefer and makes the enoxaparin provenance error. Both keep the open items (perfusion, osteomyelitis, disposition) appropriately open.

Methodology: Both read the chart broadly, reconcile against the MAR and the held-order set, and check the images against the report. A's synthesis is more careful on the carried-forward status of enoxaparin; B's faster pass produces the provenance mislabel.

Quality and clarity: Both are organized and sign-ready, with clear verdict columns and a confirm-before-sign list. A's presentation is more cautious and complete; B's is cleaner but briefer, and its "New" enoxaparin label, though presented confidently, is incorrect.

Summary: A is preferred with A+ because it handles the central enoxaparin item more faithfully (correct provenance, fuller bleeding-risk framing) and is more complete, while B mislabels the carried-forward enoxaparin as new. The margin is A+ rather than A++ because neither transcript makes the golden's affirmative move of discontinuing the inpatient-only enoxaparin at discharge; A defers it to confirmation rather than stopping it.

## Guardrails (must survive any edit)
1. Preferred output is A.
2. Use A+, not A++: A does not affirmatively discontinue the inpatient-only enoxaparin; it defers to confirmation.
3. The decider is the central enoxaparin and held-agent handling, not prose polish, formatting, or the offer to draft a corrected order set.
4. B's "New (not on MAR/home list)" enoxaparin label is a provenance error on the central item; record it as the deciding correctness gap.
5. PL 1 of 3 for OV01; remaining PLs on distinct pairs.

## Submit mechanics
Select A+ (one plus sign), paste the justification from "Preferred output: A" through the Summary into Comments, submit the preference, confirm it appears in submission history, then run Preference Labels AutoQC. Do not submit until Alexander authorizes this exact step.
